• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Neumora Therapeutics Inc.

    11/12/24 4:30:30 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NMRA alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    United States

    Securities and Exchange Commission

    Washington, D.C. 20549

     

    Schedule 13G

     

    (Rule 13d-102)

     

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (Amendment No.   )*

     

    Neumora Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    640979100

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 640979100 Schedule 13G Page 1 of 12

     

    1

    Names of Reporting Persons

     

    SoftBank Group Corp.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐
    3

    SEC Use Only

     

     
    4

    Citizenship or Place of Organization

     

    Japan

     

    Number of Shares Beneficially Owned by Each Reporting Person With 5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    7,546,916

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    7,546,916

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,546,916

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    4.7%

    12

    Type of Reporting Person

     

    CO

     

     

     

     

    CUSIP No. 640979100 Schedule 13G Page 2 of 12

     

    1

    Names of Reporting Persons

     

    SB Global Advisers Limited

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Citizenship or Place of Organization

     

    England and Wales

     

    Number of Shares Beneficially Owned by Each Reporting Person With 5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    7,546,916

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    7,546,916

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,546,916

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    4.7%

    12

    Type of Reporting Person

     

    CO

     

     

     

     

    CUSIP No. 640979100 Schedule 13G Page 3 of 12

     

    1

    Names of Reporting Persons

     

    SoftBank Vision Fund II-2 L.P.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐
    3

    SEC Use Only

     

     
    4

    Citizenship or Place of Organization

     

    Jersey

     

    Number of Shares Beneficially Owned by Each Reporting Person With 5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    7,546,916

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    7,546,916

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,546,916

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    4.7%

    12

    Type of Reporting Person

     

    PN

     

     

     

     

    CUSIP No. 640979100 Schedule 13G Page 4 of 12

     

    1

    Names of Reporting Persons

     

    SVF II Aggregator (Jersey) L.P.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Citizenship or Place of Organization

     

    Jersey

     

    Number of Shares Beneficially Owned by Each Reporting Person With 5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    7,546,916

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    7,546,916

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,546,916

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    4.7%

    12

    Type of Reporting Person

     

    PN

     

     

     

     

    CUSIP No. 640979100 Schedule 13G Page 5 of 12

     

    1

    Names of Reporting Persons

     

    SVF II Holdings (DE) LLC

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Citizenship or Place of Organization

     

    Delaware

     

    Number of Shares Beneficially Owned by Each Reporting Person With 5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    7,546,916

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    7,546,916

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,546,916

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    4.7%

    12

    Type of Reporting Person

     

    OO (Limited Liability Company)

     

     

     

     

    CUSIP No. 640979100 Schedule 13G Page 6 of 12

     

    1

    Names of Reporting Persons

     

    SVF II Investment Holdings LLC

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Citizenship or Place of Organization

     

    Delaware

     

    Number of Shares Beneficially Owned by Each Reporting Person With 5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    7,546,916

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    7,546,916

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,546,916

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    4.7%

    12

    Type of Reporting Person

     

    OO (Limited Liability Company)

     

     

     

     

    CUSIP No. 640979100 Schedule 13G Page 7 of 12

     

    1

    Names of Reporting Persons

     

    SVF II Investment Holdings (Subco) LLC

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Citizenship or Place of Organization

     

    Delaware

     

    Number of Shares Beneficially Owned by Each Reporting Person With 5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    7,546,916

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    7,546,916

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,546,916

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    4.7%

    12

    Type of Reporting Person

     

    OO (Limited Liability Company)

     

     

     

     

    CUSIP No. 640979100 Schedule 13G Page 8 of 12

     

    1

    Names of Reporting Persons

     

    SVF II AIV (DE) LLC

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Citizenship or Place of Organization

     

    Delaware

     

    Number of Shares Beneficially Owned by Each Reporting Person With 5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    7,546,916

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    7,546,916

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,546,916

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    4.7%

    12

    Type of Reporting Person

     

    OO (Limited Liability Company)

     

     

     

     

    CUSIP No. 640979100 Schedule 13G Page 9 of 12

     

    ITEM 1. (a)Name of Issuer:

     

    Neumora Therapeutics, Inc. (the “Issuer”).

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    490 Arsenal Way, Suite 200, Watertown, MA 02472

     

    ITEM 2. (a)Name of Person Filing:

     

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

     

    SoftBank Group Corp. (“SoftBank”)

    SB Global Advisers Limited (“SBGA”)

    SoftBank Vision Fund II-2 L.P.

    SVF II Aggregator (Jersey) L.P.

    SVF II Holdings (DE) LLC

    SVF II Investment Holdings LLC

    SVF II Investment Holdings (Subco) LLC

    SVF II AIV (DE) LLC

     

    (b)Address or Principal Business Office:

     

    The address of SoftBank is 1-7-1, Kaigan, Minato-ku Tokyo 105-7537 Japan. The address for SBGA is 69 Grosvenor Street, London W1K 3JP, United Kingdom. The address for each of SoftBank Vision Fund II-2 L.P. and SVF II Aggregator (Jersey) L.P. is c/o Gen II (Jersey) Limited, 47 The Esplanade, St. Helier, Jersey JE1 0BD. The address for each of the remaining Reporting Persons is 251 Little Falls Drive, Wilmington, Delaware, 19808.

     

    (c)Citizenship of each Reporting Person is:

     

    SoftBank is organized under the laws of Japan. SBGA is organized under the laws of England and Wales. Each of SoftBank Vision Fund II-2 L.P. and SVF II Aggregator (Jersey) L.P. is organized under the laws of Jersey. Each of the remaining Reporting Persons is organized under the laws of the State of Delaware.

     

    (d)Title of Class of Securities:

     

    Common stock, par value $0.0001 per share (“Common Stock”).

     

    (e)CUSIP Number:

     

    640979100

     

     

     

     

    CUSIP No. 640979100 Schedule 13G Page 10 of 12

     

    ITEM 3.

     

    Not applicable.

     

    ITEM 4.Ownership.

     

    (a-c)

     

    The ownership information presented below represents beneficial ownership of the shares of Common Stock as of September 30, 2024, based upon 160,027,746 shares of Common Stock outstanding as of August 1, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024.

     

    Reporting Person 

    Amount

    beneficially

    owned

     

    Percent

    of class:

      Sole power to vote or to direct the vote:  Shared power to vote or to direct the vote: 

    Sole power to dispose or to direct the disposition

    of:

     

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

    SoftBank Group Corp.   7,546,916    4.7%   0    7,546,916    0    7,546,916 
    SB Global Advisers Limited   7,546,916    4.7%   0    7,546,916    0    7,546,916 
    SoftBank Vision Fund II-2 L.P.   7,546,916    4.7%   0    7,546,916    0    7,546,916 
    SVF II Aggregator (Jersey) L.P.   7,546,916    4.7%   0    7,546,916    0    7,546,916 
    SVF II Holdings (DE) LLC   7,546,916    4.7%   0    7,546,916    0    7,546,916 
    SVF II Investment Holdings LLC   7,546,916    4.7%   0    7,546,916    0    7,546,916 
    SVF II Investment Holdings (Subco) LLC   7,546,916    4.7%   0    7,546,916    0    7,546,916 
    SVF II AIV (DE) LLC   7,546,916    4.7%   0    7,546,916    0    7,546,916 

     

    SVF II AIV (DE) LLC is the record holder of the shares of Common Stock reported herein.

     

    SoftBank, which is a publicly traded company listed on the Tokyo Stock Exchange, is the sole shareholder of SBGA, which has been appointed as manager and is responsible for making final decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund II-2 L.P.’s investments. SoftBank Vision Fund II-2 L.P. is the sole limited partner of SVF II Aggregator (Jersey) L.P., which is the sole member of SVF II Holdings (DE) LLC, which is the managing member of SVF II Investment Holdings LLC, which is the sole member of SVF II Investment Holdings (Subco) LLC, which is the sole member of SVF II AIV (DE) LLC. As a result of these relationships, each of the Reporting Persons may be deemed to share beneficial ownership of the securities reported herein.

     

    ITEM 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following: ☒

     

    ITEM 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    ITEM 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    ITEM 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    ITEM 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    ITEM 10.Certification.

     

    Not applicable.

     

     

     

     

    CUSIP No. 640979100 Schedule 13G Page 11 of 12

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 12, 2024

     

      SoftBank Group Corp.
         
      By: /s/ Yuko Yamamoto
      Name: Yuko Yamamoto
      Title: Head of Corporate Legal Department
         
      SB Global Advisers Limited
         
      By: /s/ Alex Clavel
      Name: Alex Clavel
      Title: Director
         
      SoftBank Vision Fund II-2 L.P.
       
      By: SB Global Advisers Limited, its Manager
         
      By: /s/ Alex Clavel
      Name: Alex Clavel
      Title: Director
         
      SVF II Aggregator (Jersey) L.P.
         
      By: SVF II GP (Jersey) Limited, its General Partner
         
      By: /s/ Michael Johnson
      Name: Michael Johnson
      Title: Director
         
      SVF II Holdings (DE) LLC
         
      By: /s/ Jonathan Duckles
      Name: Jonathan Duckles
      Title: Director
         
      SVF II Investment Holdings LLC
         
      By: /s/ Jonathan Duckles
      Name: Jonathan Duckles
      Title: Director
         
      SVF II Investment Holdings (Subco) LLC
         
      By: /s/ Jonathan Duckles
      Name: Jonathan Duckles
      Title: Director
         
      SVF II AIV (DE) LLC
         
      By: /s/ Jonathan Duckles
      Name: Jonathan Duckles
      Title: Director

     

     

     

     

    CUSIP No. 640979100 Schedule 13G Page 12 of 12

     

    LIST OF EXHIBITS

     

    Exhibit No.   Description
    99   Joint Filing Agreement (previously filed).

     

     

     

    Get the next $NMRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NMRA

    DatePrice TargetRatingAnalyst
    4/2/2025$1.00Buy → Underperform
    BofA Securities
    3/10/2025Outperform → Mkt Perform
    William Blair
    3/7/2025Buy → Neutral
    Guggenheim
    3/7/2025$6.00 → $2.00Buy → Hold
    Stifel
    1/2/2025$29.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    11/5/2024$18.00 → $15.00Overweight → Neutral
    JP Morgan
    10/1/2024$30.00Buy
    H.C. Wainwright
    7/22/2024$23.00Buy
    Needham
    More analyst ratings

    $NMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Monday, May 12, 2025 to report its first quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Part

      4/28/25 7:00:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Galapagos Announces Executive Leadership Updates

      Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo  Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the next 12 months and plans to continue as Chair of the Board of Directors, ensuring leadership continuity and long-term strategic guidance Mechelen, Belgium; April 21, 2025, 22:10 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today makes two executive leadership announcements. In line with its planned separation

      4/21/25 4:10:00 PM ET
      $GLPG
      $NMRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Neumora Therapeutics to Present at Leerink Global Healthcare Conference

      WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will present at the Leerink Global Healthcare Conference being held in Miami, FL on Tuesday, March 11, 2025 at 10:00 a.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About NeumoraNeumora Therapeutics, Inc.

      3/4/25 8:30:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NMRA
    Financials

    Live finance-specific insights

    See more
    • Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Monday, May 12, 2025 to report its first quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Part

      4/28/25 7:00:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics Announces Leadership Transition

      Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board Joshua Pinto, Ph.D. to serve as president Bill Aurora, Pharm.D. to serve as chief operating and development officer; Michael Milligan to serve as chief financial officer Neumora to host conference call on March 3, 2025 to report its fourth quarter and full year 2024 financial results and provide a business update WATERTOWN, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced th

      2/13/25 7:00:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 Ongoing clinical studies evaluating navacaprant in bipolar depression and NMRA-511 in Alzheimer's disease agitation with data expected in second half of 2025 Clinical study for next M4 PAM program expected to commence clinical in the first half of 2025 Strong financial position with $341.3 million in cash, cash equivalents and marketable securities now expected to support operations into mid-2026 Conference call today at 8:00am ET WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neumora Therape

      11/12/24 7:00:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Neumora Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Neumora Therapeutics from Buy to Underperform and set a new price target of $1.00

      4/2/25 8:47:48 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics downgraded by William Blair

      William Blair downgraded Neumora Therapeutics from Outperform to Mkt Perform

      3/10/25 7:56:32 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics downgraded by Guggenheim

      Guggenheim downgraded Neumora Therapeutics from Buy to Neutral

      3/7/25 8:22:06 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NMRA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Neumora Therapeutics Inc.

      DEFA14A - Neumora Therapeutics, Inc. (0001885522) (Filer)

      4/29/25 4:06:06 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Neumora Therapeutics Inc.

      DEF 14A - Neumora Therapeutics, Inc. (0001885522) (Filer)

      4/29/25 4:03:56 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Neumora Therapeutics Inc.

      PRE 14A - Neumora Therapeutics, Inc. (0001885522) (Filer)

      4/11/25 4:55:32 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Neumora Therapeutics Inc.

      SC 13D/A - Neumora Therapeutics, Inc. (0001885522) (Subject)

      11/22/24 5:33:43 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Neumora Therapeutics Inc.

      SC 13G - Neumora Therapeutics, Inc. (0001885522) (Subject)

      11/12/24 4:30:30 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Berns Paul L sold $23,468 worth of shares (13,871 units at $1.69), decreasing direct ownership by 0.19% to 7,405,004 units (SEC Form 4)

      4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

      2/20/25 5:14:53 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Milligan Michael Lee sold $3,351 worth of shares (1,978 units at $1.69), decreasing direct ownership by 8% to 22,470 units (SEC Form 4)

      4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

      2/20/25 5:14:01 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Strategy Officer Aurora Daljit Singh sold $14,347 worth of shares (8,565 units at $1.68), decreasing direct ownership by 9% to 88,935 units (SEC Form 4)

      4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

      2/20/25 5:13:14 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

      On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024 Strong financial position with $463.8 million in cash, cash equivalents and marketable securities expected to support operations into 2026 WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update. "2023 was a watershed year for Neumora as we

      3/7/24 7:00:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

      WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora's executive team, reporting to Henry Gosebruch, president and chief executive officer. Ms. Pai Panandiker has more than 20 years of experience commercializing medicines in areas of significant unmet need, including the commercial launches of TRINTELLIX® (vortioxetine) and REXULTI® (brexpiprazole) for major depressive disorder (MDD) and schizophrenia. "I am excited to welcome Kaya to Neumora. As we progress t

      1/22/24 7:00:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

      WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Jason Duncan as chief legal officer. Mr. Duncan will be a member of Neumora's Executive Team, reporting to Henry Gosebruch, chief executive officer, and will oversee all aspects of the Company's legal and compliance functions. "I am pleased to welcome Jason to Neumora. With his unique background that combines legal expertise with program strategy, I am confident that he will be a valuable addition to our team as we seek to deliver on our mission to redefine neuroscience drug dev

      12/12/23 7:00:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care